

Format for disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A - Details of the Acquisition

Name of the Target Company (TC)	Sudeep Pharma Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Nuvama Crossover Opportunities Fund – Series III Nuvama Crossover Opportunities Fund – Series IIIA Nuvama Crossover Opportunities Fund – Series IIIB Nuvama Crossover Opportunities Fund – Series IVA		
Whether the acquirer belongs to Promoter / Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	NSE, BSE		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of: a) Shares carrying voting rights b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others) c) Voting rights (VR) otherwise than by shares d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) e) Total (a+b+c+d)	a) Nil <i>(This submission is for selling current holdings exceeding 2% of the Total shareholding of the company acquired on and before the IPO)</i>	a) NA	a) NA
Details of acquisition a) Shares carrying voting rights acquired b) VRs acquired otherwise than by equity shares c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	a) 94,51,295 (shares were acquired before and during IPO)	a) 8.4%	a) 8.4%

d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
e) Total (a+b+c+/-d)	94,51,295	8.4%	8.4%
After the acquisition, holding of acquirer along with PACs of:	a) 94,51,295	8.4%	8.4%
a) Shares carrying voting rights			
b) VRs otherwise than by equity shares			
c) Warrants/convertible securities /any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
e) Total (a+b+c+d)	94,51,295	8.4%	8.4%
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer / encumbrance, etc.)	Combination of Preferential allotment (for Pre IPO) and Open market (for IPO)		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	CCPS converted to equity shares at 1:1 ratio before IPO		
Date of acquisition of shares	Multiple dates, starting from 09-07-2024 (First allotment date), until 27-11-2025 (IPO allotment date)		
Equity share capital / total voting capital of the TC before the said acquisition	As on 09-07-2024: 49,31,850 (since then there have been bonus issue, stock split, pre-IPO funding and IPO event)		
Equity share capital/ total voting capital of the TC after the said acquisition	11,29,48,625		
Total diluted share/voting capital of the TC after the said acquisition	11,29,48,625		

Part-B*****Name of the Target Company:** Sudeep Pharma Limited

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/ or PACs
Nuvama Crossover Opportunities Fund – Series III	No	
Nuvama Crossover Opportunities Fund – Series IIIA	No	
Nuvama Crossover Opportunities Fund – Series IIIB	No	
Nuvama Crossover Opportunities Fund – Series IVA	No	

**Signature of Authorised Signatory:**

Place: Mumbai

Date: 28/07/2026

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.